-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GlaxoSmithKline sold the rights to an experimental treatment with potential psoriasis and dermatitis for $330 million.
Tapinarof is a research therapeutic aromatic hydrocarbon regulator (TAMA) that has been evaluated as atypical in several studies involving more than 800 subjects in Phases I and II.
In a placebo-controlled global IIb dose range study, 56 percent of patients with 1 percent tapinarof and 46 percent of patients with 0.5 percent tapinarof improved at least 75 percent in psoriasis area and severity index scores (PASI) after 12 weeks of treatment.
John Lepore, senior vice president of research and development pipelines at GlaxoSmithKline, explained the reasons for the sale, saying the company had made a strategic decision to spin off or co-develop its research and development portfolio "more suited to other companies and allow us to focus our resources on other promising assets".
Said: "Tapinarof has the potential to be a first-class treatment and a daily topical drug that can delay or even eliminate systemic treatments for psoriasis and endexual dermatitis. We are confident that Dermavant is fully capable of making rapid progress in the third phase and registration of the Tapinarof development plan. Thepainkillers disputethe pharmaceutical giant lost a BRITISH dispute over the names of over-the-counter drugs.
Apollo Generics applied in October 2016 to register its brand Zanamol as a UK trademark, but GSK objected, citing its name and category specifications that were too similar to paracelione painkiller Panadol.
GlaxoSmithKline said there could be confusion between the trademarks, but UKIP disagreed and backed Apollo's ruling. (This web article)